Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme Exclusively Licenses Trans-Lentiviral Vector Technology to Open Biosystems

NEW YORK, Nov. 14 (GenomeWeb News) - Open Biosystems has obtained an exclusive license to use Tranzyme Pharma's trans-lentiviral gene-expression technology, the company said today.


Under the agreement, Open Biosystems can develop and commercialize products based on the gene-expression technology. Open Biosystems will assume Tranzyme's Birmingham, Ala., operations and expand lentiviral-based product development and production.


Tranzyme will receive minimum annual payments and royalties on sales of products and services that depend on its technology, Open Biosystems said. The amount for the minimum payments was not disclosed.


Tranzyme's human-based trans-lentiviral gene expression technology can be used in neuroscience research, and Open Biosystems will provide proprietary research reagents and services based on lentiviral vectors.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.